Mutagenicity studies of benzalazine.
Benzalazine (2-hydroxy-5-[(4-carboxyphenyl) azo] benzoic acid, CAS 64896-26-0), a new agent for the treatment of ulcerative colitis and Crohn's disease of the large intestine, was studied for genotoxic effects by using the following short-term in vitro and in vivo test: 1. reverse mutation test (Ames method) on Salmonella typhimurium, 2. HGPRT (hypoxanthine-guanine phosphoribosyl transferase) point mutation test on V79 hamster cells, 3. in vivo cytogenetic test on Chinese hamster cells, and 4. in vivo sister chromatid exchange test on Chinese hamster cells. Benzalazine did not show any positive response in the reverse mutation test, HGPRT-point mutation test, in vivo cytogenetic and sister chromatid exchange test.
Henning Berlin GmbHa, Fed. Rep. of Germany.
R
R
Herzog
J
J
Leuschner
D000818:Animals; D001547:Benzaldehydes / Q000633:toxicity*; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D005260:Female; D006835:Hydrazones / Q000633:toxicity*; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D066298:In Vitro Techniques; D008297:Male; D008677:Metaphase / Q000187:drug effects; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D009154:Mutation / Q000187:drug effects; D017354:Point Mutation / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012486:Salmonella typhimurium / Q000187:drug effects / Q000235:genetics; D012854:Sister Chromatid Exchange
D001547:Benzaldehydes; D006835:Hydrazones; D009153:Mutagens; C085292:benzalazine; D007041:Hypoxanthine Phosphoribosyltransferase